The future of B cell-targeted therapies in Sjögren's syndrome

Immunotherapy

Volumn 5, Issue 6, 2013, Pages 639-646

  Cornec, Divi ^a,b   Saraux, Alain ^a,b   Devauchelle Pensec, Valérie ^a,b   Clodic, Coralie ^c   Pers, Jacques Olivier ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Universite de Brest   (France)

^c CHU MORVAN   (France)

Author keywords

B cell; biotherapy; rituximab; Sj gren's syndrome

Indexed keywords

BAMINERCEPT; BELIMUMAB; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RITUXIMAB; SARILUMAB; SBI 087; SILTUXIMAB; SIRUKUMAB; TABALUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VELTUZUMAB;

B LYMPHOCYTE; CELL SUBPOPULATION; CELL THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SJOEGREN SYNDROME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; LYMPHOTOXIN-BETA; SIALIC ACID BINDING IG-LIKE LECTIN 2; SJOGREN'S SYNDROME;

EID: 84878744166     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.49     Document Type: Review

References (65)

1. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 91(1), 1-9 (2012).
2. Cornec D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J. Autoimmun. 39(3), 161-167 (2012).
3. Fauchais AL, Martel C, Gondran G et al. Immunological profile in primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun. Rev. 9(9), 595-599 (2010).
4. Malladi AS, Sack KE, Shiboski SC et al. Primary Sjogren's syndrome as a systemic disease: a study of participants enrolled in an international Sjogren's syndrome registry. Arthritis Care Res. (Hoboken) 64(6), 911-918 (2012).
5. Scofield RH, Farris AD, Horsfall AC, Harley JB. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum. 42(2), 199-209 (1999).
6. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61(6), 554-558 (2002).
7. Peene I, Meheus L, Veys EM, De Keyser F. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann. Rheum. Dis. 61(12), 1090-1094 (2002).
8. Bendaoud B, Pennec YL, Lelong A et al. IgA-containing immune complexes in the circulation of patients with primary Sjogren's syndrome. J. Autoimmun. 4(1), 177-184 (1991).
9. Shiboski SC, Shiboski CH, Criswell LA et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res. 64(4), 475-487 (2012).
10. Haneji N, Nakamura T, Takio K et al. Identification of a-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 276(5312), 604-607 (1997).
11. Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? Arthritis Rheum. 52(10), 2984-2995 (2005).
12. Blaschek MA, Pennec YL, Simitzis AM et al. Anti-Golgi complex autoantibodies in patients with primary Sjogren's syndrome. Scand. J. Rheumatol. 17(4), 291-296 (1988).
13. Collins K, Mitchell S, Griffiths B, Bowman SJ, Ng WF. Potential diagnostic utility of anti-centromere antibody in primary Sjogren's syndrome in the UK. Clin. Rheumatol. 31(7), 1147-1148 (2012).
14. Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren's syndrome. Arthritis Res. Ther. 13(4), 227 (2011).
15. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264 (2003).
16. Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B cell tolerance breakdown in Sjogren's syndrome: focus on BAFF. Autoimmun. Rev. 9(9), 604-608 (2010).
17. Pers JO, Daridon C, Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N. Y. Acad. Sci. 1050, 34-39 (2005).
18. Pers JO, D'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary BAFF in Sjogren's syndrome? Arthritis Rheum. 52(8), 2411-2414 (2005).
19. Youinou P, Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders. J. Autoimmun. 32(3-4), 206-210 (2009).
20. Hillion S, Dueymes M, Youinou P, Jamin C. IL-6 contributes to the expression of RAGs in human mature B cells. J. Immunol. 179(10), 6790-6798 (2007).
21. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361(9), 888-898 (2009).
22. Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS. Surface lymphotoxin a/b complex is required for the development of peripheral lymphoid organs. J. Exp. Med. 184(5), 1999-2006 (1996).
23. Van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10(9), 664-674 (2010).
24. Le Pottier L, Devauchelle V, Fautrel A et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J. Immunol. 182(6), 3540-3547 (2009).
25. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 52(5), 1534-1544 (2005).
26. Hansen A, Odendahl M, Reiter K et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 46(8), 2160-2171 (2002).
27. D'Arbonneau F, Pers JO, Devauchelle V, Pennec Y, Saraux A, Youinou P. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum. 54(1), 115-126 (2006).
28. Pascual V, Liu YJ, Magalski A, De Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med. 180(1), 329-339 (1994).
29. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167(7), 3610-3618 (2001).
30. Binard A, Le Pottier L, Devauchelle-Pensec V, Saraux A, Youinou P, Pers JO. Is the blood B cell subset profile diagnostic for Sjogren syndrome? Ann. Rheum. Dis. 68(9), 1447-1452 (2009).
31. Daridon C, Pers JO, Devauchelle V et al. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 54(7), 2280-2288 (2006).
32. Guerrier T, Le Pottier L, Devauchelle V, Pers JO, Jamin C, Youinou P. Role of toll-like receptors in primary Sjogren's syndrome with a special emphasis on B cell maturation within exocrine tissues. J. Autoimmun. 39(1-2), 69-76 (2012).
33. Theander E, Vasaitis L, Baecklund E et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann. Rheum. Dis. 70(8), 1363-1368 (2011).
34. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63(8), 803-843 (2003).
35. Edwards JCW, Szczepanski L, Szechinski J et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
36. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64(6), 913-920 (2005).
37. Pijpe J, Van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 52(9), 2740-2750 (2005).
38. Seror R, Sordet C, Guillevin L et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann. Rheum. Dis. 66(3), 351-357 (2007).
39. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann. Rheum. Dis. 68(2), 284-285 (2009).
40. Mekinian A, Ravaud P, Hatron PY et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann. Rheum. Dis. 71(1), 84-87 (2012).
41. Mekinian A, Ravaud P, Larroche C et al. Rituximab in central nervous system manifestations of patients with primary Sjogren's syndrome: results from the AIR registry. Clin. Exp. Rheumatol. 30(2), 208-212 (2012).
42. Gottenberg JE, Cinquetti G, Larroche C et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. doi:10.1136/ annrheumdis-2012-202293 (2012) (Epub ahead of print).
43. St Clair EW, Levesque MC, Luning Prak ET et al. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 65(4), 1097-1106 (2013).
44. Devauchelle-Pensec V, Pennec Y, Morvan J et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57(2), 310-317 (2007).
45. Devauchelle-Pensec V, Morvan J, Rat AC et al. Effects of rituximab therapy on quality of life in patients with primary Sjogren's syndrome. Clin. Exp. Rheumatol. 29(1), 6-12 (2011).
46. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum. 56(5), 1464-1477 (2007).
47. Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67(11), 1541-1544 (2008).
48. Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62(4), 960-968 (2010).
49. Devauchelle-Pensec V, Xavier M, Jousse-Joulin S et al.; the TEARS study group. Tolerance and efficacy of rituximab in primary Sjogren syndrome (TEARS): results of the randomized controlled trial. EULAR congress. Ann. Rheum. Dis. 71, 75 (2012).
50. Devauchelle-Pensec V, Xavier M, Jousse-Joulin S et al. Tolerance and efficacy of rituximab in primary Sjogren syndrome: final results of a randomized controlled trial. Arthritis Rheum. 64(Suppl. 10), Abstract 2554 (2012).
51. Leonard JP, Schuster SJ, Emmanouilides C et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, Phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113(10), 2714-2723 (2008).
52. Lindén O, Hindorf C, Cavallin-Ståhl E et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin. Cancer Res. 11(14), 5215-5222 (2005).
53. Wallace DJ, Kalunian K, Petri MA et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a Phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. doi:10.1136/annrheumdis- 2012-202760 (2013) (Epub ahead of print).
54. Steinfeld SD, Tant L, Burmester GR et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label Phase I/II study. Arthritis Res. Ther. 8(4), R129 (2006).
55. Furie R, Petri M, Zamani O et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63(12), 3918-3930 (2011).
56. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9767), 721-731 (2011).
57. Genovese MC, Bojin S, Biagini I et al. Tabalumab in patients with rheumatoid arthritis with an inadequate response to methotrexate and naive to biologic therapy. Arthritis Rheum. 65(4), 880-889 (2013).
58. Genovese MC, Fleischmann RM, Greenwald M et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann. Rheum. Dis. doi:10.1136/annrheumdis- 2012-202775 (2012) (Epub ahead of print).
59. Le Pottier L, Bendaoud B, Renaudineau Y, Youinou P, Pers JO, Daridon C. New ELISA for B cell-activating factor. Clin. Chem. 55(10), 1843-1851 (2009).
60. Efficacy and safety of belimumab in subjects with primary Sjogren's syndrome (BELISS). http://clinicaltrials.gov/show/NCT01160666
61. Efficacy and safety of belimumab in primary Sjogren's syndrome. http://clinicaltrials.gov/show/NCT01008982
62. A study of LY2127399 in patients with systemic lupus erythematosus. http://clinicaltrials.gov/show/NCT01205438
63. A study of patients with relapsing remitting multiple sclerosis. http://clinicaltrials.gov/show/NCT00882999
64. Efficacy of tocilizumab in primary Sjogren's syndrome (ETAP). http://clinicaltrials.gov/show/NCT01782235
65. Baminercept in Sjogren's syndrome. http://clinicaltrials.gov/show/ NCT01552681